Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Product news (11 September 2010)

By News team

Accessing SPCs

The list of changes to summaries of product characteristics is not exhaustive. SPCs for a number of medicines licensed in the UK are available online

SPC changes


The indication of Cervarix (human papilloma virus vaccine; GlaxoSmithKline) has been expanded to include more oncogenic HPV types.

The updated summary of product characteristics also states that if flexibility is needed in the recommended vaccination schedule (0, 1 and 6 months) then the second dose can be administered between 1 month and 2.5 months after the first dose, and the third dose between 5 and 12 months after the first dose.


Enzira (influenza vaccine; Pfizer) is only recommended for use in children aged five years and over, according to an update to the SPC that was made in response to reports of febrile convulsions in children under five years of age following administration of the vaccine.

Febrile convulsions are now listed as an adverse event.


Gammanorm (human normal immunoglobulin; Octapharma) is no longer indicated for the prophylaxis of hepatitis A and measles.

Supply issues


Isocarboxazid (Alliance) tablets are currently in short supply.

Alliance expects an unlicensed alternative to become available later this week (September 2010) and supplies of isocarboxazid to return to normal in November 2010.

Medical information on 01249 466966.


Nystan (nystatin; Bristol-Myers Squibb) oral suspension 100,000 units/ml is now back in stock.

Medical information on 01895 523 000.

Testosterone enantate

Testosterone enantate (Alliance) ampoules are now back in stock.

Medical information on 01249 466966.

Discontinued products


Zoleptil (zotepine; Movianto) tablets will be discontinued on 1 January 2011.

Medical information on 01748 828 858 (e-mail

Citation: The Pharmaceutical Journal URI: 11024168

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.